David Michael Nanus, M.D.

Medical Oncology
David Nanus

Dr. Nanus is an internationally recognized leader in the treatment and care of patients with genitourinary (GU) cancers, including cancers of the prostate, kidney, bladder and testes. He is actively involved in clinical, translational and basic research in GU malignancies, serving as principle or co-investigator on a variety of clinical research trials that incorporate novel targeted therapies for his patients. Since 2004, Dr. Nanus who is The Mark W. Pasmantier Professor of Hematology and Oncology in Medicine, has served as Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medical College. Dr. Nanus is also Associate Director of Clnical Services for the Cancer Center.  He is the recipient of numerous awards including membership in the American Society for Clinical Investigation and the American Association of Physicians.

Dr. Nanus is a graduate of the University of Illinois and the Chicago Medical School. After completing clinical training in Medicine at Albert Einstein and Medical Oncology at Memorial Sloan Kettering Cancer Center, and research training at the Sloan Kettering Institute, he was invited to join the faculty at Memorial Sloan Kettering Cancer Center in 1989. Developing a program in GU cancer, he made several important contributions to clinical and basic research in kidney and prostate cancer. He was recruited to the full-time faculty of Weill Cornell Medical College in 1998.

At Weill Cornell, Dr. Nanus helped develop the Genitourinary Oncology Research Program focused on understanding the events that contribute to the progression of urologic cancers, and on developing new and more effective therapies to treat advanced prostate, kidney and bladder cancer.  As a Director of the Genitourinary Oncology Research Laboratory, he works with a unique interdepartmental team of world class clinical researchers seeking to translate research on the molecular basis of GU cancers into improved cancer treatment.

 

Insurances

Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please feel free to contact this physician or this physician's practice as they may have individual contracts not included on this site.

  • AETNA [HMO]
  • AETNA [PPO]
  • AETNA [Medicare]
  • Aetna - Weill Cornell [POS]
  • Affinity Essential
  • Affinity Health Plan
  • Blue Priority Network
  • CIGNA
  • Emblem Select Care
  • Empire Blue Cross/Blue Shield [Pathway X]
  • Empire Blue Cross/Blue Shield [Pathway X Enhanced]
  • Empire Blue Cross/Blue Shield [PPO]
  • Empire Blue Cross/Blue Shield [EPO]
  • Empire Blue Cross/Blue Shield [HMO]
  • Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • Fidelis Care
  • GHI [CBP]
  • Health First
  • Health Insurance Plan of NY (HIP) [Medicare]
  • Health Insurance Plan of NY (HIP) [Medicaid]
  • Health Insurance Plan of NY (HIP)
  • Health Plus - Amerigroup [CHP]
  • Health Plus - Amerigroup
  • Health Republic
  • Medicaid
  • Medicare
  • Medicare [Medicare]
  • Oscar
  • Oxford Health Plans [Medicare Advantage]
  • Oxford Health Plans [Liberty]
  • Oxford Health Plans [Freedom]
  • POMCO
  • Rockefeller University - CoreSource
  • UHC Compass
  • United Empire
  • United Health Care
  • United Health Care [Medicare]
  • United Health Care [Community Plan]
  • VNSNY CHOICE Medicare [Medicare]
  • VNSNY CHOICE Medicare [HMO]

Publications

Selected from over 180 Publications


Papandreou CN, Usmani B, Geng Y, Bogenrieder T, Freeman R, Wilk S, Finstad CL, Reuter VE, Powell CT, Scheinberg D, Magill C, Scher HI, Albino AP, Nanus DM. Neutral endopeptidase 24.11 loss in prostate cancer contributes to androgen-independent progression. Nature Med 1998:33:225-2327.  PMID: 9427606

Sumitomo M, Shen R, Geng Y, Walburg M, Dai J, Geng Y, Navarro D, Boileau G, Papandreou CN, Giancotti FG, Knudsen B, Nanus DM.  Neutral endopeptidase (CD10, CALLA) inhibits prostate cancer cell migration by blocking neuropeptide-mediated focal adhesion kinase (FAK) signaling. J Clin Inv 2000:106;1399-1407.  PMID: 11104793. PMCID: PMC381465

Sumitomo M, Iwase A, Navarro D, Zheng R, Kaminetzky D, Shen R, Georgescu M-M, Nanus DM.  Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN. Cancer Cell 2004;5:67-78. PMID: 14749127

Goodman, OB Jr, Febbraio M, Simantov R, Shen R, Silverstein RL, Nanus DM. Neutral endopeptidase functions as a negative regulator of angiogenesis through proteolytic cleavage of basic fibroblast growth factor (FGF-2). J Biol Chem 2006;281:33597-605. PMID: 16940054

Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Ross JS, Bander NH.  Vascular targeted therapy with anti-PSMA monoclonal antibody J591 in patients with advanced solid tumor malignancies. J Clin Onc 2007;25:540-7.  PMID: 17290063

Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST, Dhir R, Nelson JB, de la Taille A, Allory Y, Gerstein MB, Perner S,  Pienta KJ, Chinnaiyan AM, Wang Y, Collins CC, Gleave ME, Demichelis F, Nanus DM, Rubin MA.  Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.  Cancer Discovery 2011;1:487-495. PMID: 22389870. PMCID: PMC3290518

Fu L, Wang G, Shevchuk MM, Nanus DM, Gudas LJ. Generation of a mouse model of von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1α.  Cancer Res 2011;71:6848-56. PMID:21908555

Darshan MS, Loftus M, Thadani-Mulero M, Levy BP, Escuin-Borras D, Zhou XK, Shen R, Tagawa ST, Bander NH, Nanus DM, Giannakakou P.  Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical response in metastatic prostate cancer.  Cancer Res 2011: 71:6019-29. PMID: 21799031. PMCID: PMC3354631 

Thadani-Mulero M, Nanus DM, Giannakakou P. Androgen receptor on the move: Boarding the microtubule expressway to the nucleus. Cancer Res 2012;72:4611-5. PMID:22987486. PMCID: PMC3448065

Kirby BJ, Jodari M, Loftus MS, Gakhar G, Pratt ED, Chanel-Vos C, Gleghorn JP, Santana SM, Liu H, Smith JP, Tagawa ST, Bander NH, Nanus DM, Giannakakou P. Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PLoS One 2012;7(4): e35976.  PMID: 22558290. PMCID: PMC3338784

Tagawa ST, Milowsky MI,  Morris M, Vallabhajosula S, Christos P, Akhtar NH, Osborne J, Goldsmith SJ, Larson S, Taskar NP, Scher HI, Bander NH, Nanus DM.  Phase II study of lutetium-177 labeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res 2013: 19:5182-91. PMID: 23714732. PMCID: PMC3778101

Gakhar G, Navarro VN, Jurish M, Lee GY, Akhtar N, Tagawa ST, Seandel M, Geng Y, Liu H, Bander NH, Giannakakou P, King MR, Nanus DM.  Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flow. Plos One 2013, e85143. PMID: 24386459. PMCID: PMC3874033

Thadani-Mulero M, Portella L, Sun S, Sung M, Vessella R, Nanus DM, Plymate S, Giannakakou P. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res 2014, Epub. PMID:24556717

Gudas LJ, Fu L, Minton DR, Mongan NP, Nanus DM.  The role of HIF1α in renal cell carcinoma tumorigenesis.  J Mol Med 2014, Epub. PMID:24916472

Galletti G, Portella L, Tagawa ST, Kirby BJ, Giannakakou P, Nanus DM. Circulating Tumor Cells in Prostate Cancer Diagnosis and Monitoring: An Appraisal of Clinical Potential. Mol Diagn Ther 2014  Epub. PMID:24809501.

Honors and Awards

1988   American Society of Clinical Oncology Young Investigators Award for Cancer Research

1988   American Philosophical Society Daland Fellowship for research in clinical medicine

1990   National Kidney Foundation Young Investigator Grant Award

1991   American Cancer Society Career Development Award

1998-2014  Best Doctor, Best Doctors in America

2000   Mid-Career Development Award, National Institutes of Health

2001   Member, American Society for Clinical Investigation (ASCI)

2005   Member, American Association of Physicians (AAP)

2009-14   U.S. News and World Reports Top Doctors (Castle Connolly's estimation among the top 1% in the nation in his or her specialty)

2010-14   Super Doctors (outstanding physicians who have attained a high degree of peer recognition or professional achievement)

2010   2010 Gold DOC Award for sensitivity, kindness and compassion in the practice of medicine, The Arnold P. Gold Foundation

2012-14   Consumer Research Council of America “America’s Top Oncologists”

2014   National Council of American Executives Top Ranked U.S. Executive